Vascular Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Vascular Imaging Market Trends and Insights

CVD and PAD Burden Elevates Demand for Vascular Diagnostics and Monitoring

Concerted guideline updates now mandate ankle-brachial index screening for adults over 65 and duplex or CT angiography for symptomatic peripheral arterial disease, effectively doubling the diagnostic pool worldwide. European recommendations position pre-intervention CTA or MRA as compulsory for chronic limb-threatening ischemia, embedding imaging into every revascularization workflow. Serial carotid duplex reimbursements in Japan and South Korea establish recurring revenue that was previously episodic. Cumulative procedure growth maintains a clear pull on the vascular imaging market even as modality pricing edges downward.

Shift Toward Minimally Invasive Endovascular Procedures Increases Intraprocedural Imaging Volumes

Endovascular aneurysm repair now addresses roughly 80% of abdominal cases and thoracic EVAR treats up to 80% of type B dissections, each case requiring triple-phase imaging, pre-operative CTA, cone-beam CT fusion, and completion angiography. Complex PCI volumes climbed 12% year-over-year in 2024, while randomized evidence shows OCT guidance lowers target-vessel failure by 28%, driving guideline elevation of intravascular imaging. Hybrid operating rooms surpassed 1,200 installs in North America by late 2025 and cut contrast volume 30%-40% per EVAR, expanding utilization^{[1]Society for Vascular Surgery, “Hybrid OR Survey 2025,” vascular.org}. These intraprocedural needs power resilient spending within the vascular imaging market despite capital-budget scrutiny.

CT, Ultrasound, and AI Advances Improve Diagnostic Yield and Throughput in Vascular Pathways

Photon-counting CT reduces median CTDIvol from 12.3 mGy to 3.7 mGy at half the iodine load while retaining diagnostic confidence. FDA-cleared AI platforms now segment vessels and flag pulmonary embolism or dissection within 90 seconds, trimming radiologist read time by 40% FDA. Handheld ultrasound with AI probe guidance shrinks rural time-to-diagnosis for DVT from 48 hours to 2 hours. These technology leaps sustain throughput even when technologist vacancies approach 20%, thereby easing operational bottlenecks across the vascular imaging industry.

Reimbursement Tailwinds for CCTA + FFR-CT and Intravascular Imaging Codes Accelerate Adoption

CMS doubled outpatient payment for coronary CTA from USD 175 in 2024 to USD 357.13 in 2025 and assigned USD 877 to FFR-CT in 2026 after 34% volume growth. Private insurers removed prior-authorizations, transforming coronary CTA into a gatekeeper for stable chest-pain pathways. IVUS and OCT now receive around USD 450 per vessel in the United States, while Japan lifted OCT reimbursement by 56%, spurring cross-regional uptake. Payment momentum, therefore, underpins rapid procedure expansion and cements future revenue streams within the vascular imaging market.

Technologist Shortages Cap Scanning Capacity and Extend Wait Times

Vacancy rates reached 19.4% for CT technologists and 17.4% for cardiovascular interventional roles in 2025, lengthening median hiring time to 94 days and delaying scanner purchases. European radiographer deficits hit 12,000 positions in 2024, with Brexit-related workforce exits worsening U.K. aortic-imaging queues. Cross-training sonographers and deploying AI auto-positioning offers only partial relief, underscoring a human-capital ceiling on the vascular imaging market.

Radiation Dose and Iodinated Contrast Safety/Availability Concerns Limit CT and Angiography Use

FDA dose-tracking mandates and ACR registry participation spotlight cumulative exposure that can exceed 50 mSv in lifelong aneurysm surveillance. Contrast-induced kidney injury persists in 2%-7% of renal-impaired patients, and European guidelines restrict contrast below eGFR 30 mL/min unless dialysis is on standby, excluding 8% of peripheral arterial disease cases. The 2022-2024 iohexol shortage illustrated supply fragility, forcing substitution with MRA and delaying elective CTA. These constraints temper otherwise strong growth trajectories for the vascular imaging market.

Segment Analysis

By Modality: Intravascular Precision Gains Market Traction

Intravascular imaging is forecast to post the fastest modality expansion at 8.22% CAGR as Abbott’s Ultreon 3.0 and Conavi’s hybrid IVUS-OCT automate lumen analytics and cut interpretation time 35%^{[2]FDA, “510(k) Premarket Notification Database,” fda.gov}. The vascular imaging market size for ultrasound commanded 40.24% share in 2025 and still drives point-of-care adoption, but capital intensity is pivoting to photon-counting CT where vendors promise 0.2 mm resolution and dual‐energy subtraction. Ultrasound’s portability and zero radiation sustain 5.8% annual growth, yet margin migration to premium CT and angiography systems is unmistakable. 

The vascular imaging market share for computed-tomography angiography reached a significant percentage share in 2025 and rises in tandem with AI reconstruction, while X-ray angiography benefits from hybrid-OR demand that pairs ceiling C-arms with 3D fusion software. Magnetic resonance angiography consolidates difficult renal and carotid cohorts, and nuclear medicine retains a research niche below a 5% revenue threshold.

By Procedure Type: Aortic Imaging Leads Growth Trajectory

Aortic and aneurysm imaging grows 8.65% annually as TEVAR treatment windows widen and cone-beam CT fusion lowers contrast burden 30%-40%. Coronary angiography maintains dominant revenue owing to 5,000 U.S. cath labs and guideline-mandated IVUS/OCT for complex PCI. Peripheral arterial angiography accelerates on new PAD screening recommendations, while neurovascular guidance benefits from 24-hour thrombectomy eligibility and AI triage that cuts door-to-groin time to 58 minutes. 

Single-stage EVAR enabled by intraoperative cone-beam CT reduces 30-day readmissions from 8.4% to 2.9% and illustrates the cost-avoidance case sustaining scanner replacement cycles. Deep-vein-thrombosis imaging gains consistency as CTPA risk-stratification routines enter every emergency department, bolstering vascular imaging market depth.

By Application: DVT/PE Imaging Accelerates on Protocol Standardization

Emergency-department adherence to standardized CTPA plus AI RV/LV ratio measurement fuels 7.12% CAGR in DVT/PE pathways, transforming throughput and shortening time-to-anticoagulation to 2.1 hours. Atherosclerosis still dominates revenue with 42.91% share, supported by broad CAD and PAD prevalence, but aneurysmal disorder imaging keeps rising as population aging persists. 

Compression ultrasound remains first-line for proximal DVT with 95% sensitivity, while dual-energy CT iodine-mapping refines chronic thromboembolic pulmonary-hypertension surgery planning in Japan. Opportunistic carotid screening identifies ≥70% stenosis in 4.2% of risk patients and reinforces cross-modality pull on duplex and CTA systems.

By End User: ASCs Capture Procedural Migration

The ASC cohort grows 9.53% annually after CMS expanded its procedure list and equalized site payment, prompting 82% of U.S. hospitals to own at least one ASC and 47% to budget angiography installs within two years. Hospitals still hold 51.45% of 2025 revenue but confront labor inflation that spurs referral of routine angiograms to lower-cost settings. 

Diagnostic imaging centers consolidate under private equity, radiology partners manages 400 centers and secures 15%-20% equipment discounts, tilting purchasing leverage against OEMs. Academic institutes drive ultra-high-field MRA research and secure grants for photon-counting dose studies, ensuring an innovation loop inside the vascular imaging industry.

Geography Analysis

North America controls 39.35% of 2025 revenue thanks to 1,200 hybrid ORs, early FFR-CT reimbursement, and an installed base exceeding 5,000 cath labs. Yet technologist vacancies lengthen elective CTA wait times from 12 days in 2023 to 18 days in 2025, creating latent demand buffered by AI workflow tools. 

Asia-Pacific delivers the fastest regional CAGR at 9.12%, driven by China’s CNY 1 trillion (USD 0.15 trillion) hospital build-out and India’s Production-Linked Incentive that subsidizes domestic CT and ultrasound manufacturing^{[3]National Health Commission of China, “14th Five-Year Plan for Healthcare Infrastructure,” nhc.gov.cn}. United Imaging captured 18% of new CT installs in tier-1 Chinese cities by Q4 2024 after pricing photon-counting systems 25% below incumbents. Japan lifted the OCT reimbursement 56%, reinforcing premium adoption curves. 

Europe’s significant share faces MDR/IVDR attrition that places 40% of legacy devices at withdrawal risk and lifts compliance cost 30%, favoring vendors with deep notified-body ties. The Middle East and Africa grow off a small base, Saudi Arabia’s USD 64 billion Vision 2030 spend anchors GCC demand and delivered the region’s first photon-counting CT in June 2024. South America’s 5% share is steady, with Brazil and Argentina adopting refurbished angiography systems to offset currency volatility.